Endophenotyping with fMRI: Genetic modulation and treatment response
- Conditions
- F10.2
- Registration Number
- DRKS00003341
- Lead Sponsor
- Charité Campus Charité Mitte
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 440
Healthy Controls
- men and women, aged 18 to 75
- legally effective, written informed consent for participation within the study
- right handedness
- no psychiatric disorder according to ICD 10
- no psychotropic substances within the last 7 days
Alcohol-depdent patients
- men and women, aged 18 to 75
- legally effective, written informed consent for participation within the study
- right handedness
- no other psychiatric disorder according to ICD 10
- no psychotropic substances within the last 7 days
- physical disorders, which might interfere with the planned examination (z.B. cerebro-organic disorder)
- MR-contraindication (z.B. pace maker, metalic or electronic implants, metal splinters, Operationsklammern)
- anamnestic manifeste psychiatric axis I disorder and/or axis II according to ICD-10 except alcohol dependence for patients
- medication or drug dependence
- medication or drug abuse (randomisized urin testing)
- insufficient knowledge of German language
- claustrophobia
- for women: pregnancy (exclusion via pregnancy test)
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The aim of the present multicenter study in Berlin, Bonn and Mannheim is to use fMRI in alcohol addiction for endophenotyping in order to study the relevance of genetic variation, in particular in dopaminergic and glutamatergic genes, for addiction.
- Secondary Outcome Measures
Name Time Method test the impact of genetic variation (within important candidate genes for alcohol dependence using genetic analysis) on activation of the mesolimbic system in alcohol-dependent patients and healthy controls (measured with fMRI) and test their predictive effects for treatment outcome in alcoholics (assessed during 6 months follow-up period)<br>